Modeling tumor differences to guide new treatments for resistant small cell lung cancer
Official title: Modeling tumor heterogeneity, to develop new therapeutic strategies for treatment of resistant small cell lung cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11445820 · Data updated 2026-11-12
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 4, 2020 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $157,343 |
| NIH project number | 2R50CA243698-06A1 |
| Project ID | NIH-11445820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer, especially those who have relapsed or show resistance to current therapies.
✕Less likely to help
Patients without relapsed disease or without access to the specific therapies being explored may not benefit.
What this research studies
This project centers on small cell lung cancer, a fast-growing cancer that often stops responding to standard treatments. Researchers will study tumor diversity and how it changes after therapy, using patient-derived models and advanced analyses to find new therapeutic opportunities. The team has a strong track record in molecular profiling and biobank resources to link tumor features with response to surface-targeting drugs and antibody-drug conjugates. Results could point to new strategies to overcome resistance and improve outcomes for patients with relapsed disease.
Why it matters
Potential benefit: If successful, the work could lead to better, more effective treatment options for patients with relapsed small cell lung cancer.
How similar studies have gone: Prior work shows that profiling tumor heterogeneity and liquid biopsies can inform treatment choices and guide new therapies, with promising signals in surface-targeting approaches.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Stewart, Catherine Allison — University of Tx Md Anderson Can Ctr
- Study coordinator: Stewart, Catherine Allison
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
-
Telomere-targeting Therapy plus cemiplimab for advanced NSCLC
A new drug called THIO, used with an immune therapy, is being tested for people with advanced non-small cell lung cancer whose previous treatments stopped working.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.